Juvenile Bipolar Research Foundation Inc.
Juvenile Bipolar Research Foundation Inc.
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Juvenile Bipolar Research Foundation Inc.? Learn more here.
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.
About this organization
Mission
TO RAISE AND DISTRIBUTE FUNDS FOR THE MOST PROMISING RESEARCH INTO THE CAUSES, TREATMENT AND PREVENTION OF EARLY-ONSET BIPOLAR DISORDER. In particular, we aim to further investigate and promote awareness of the fear of harm phenotype which our research has identified as being simultaneously associated with a distinct biomaker as well as the symptoms of childhood-onset bipolar disorder.
About
Research An fMRI Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults with Bipolar Disorder Fear of Harm Phenotype proposed by Martin Teicher, M.D. Ph.D of Harvard Medical School has been peer reviewed and was approved for funding by the board. The study is planned to get underway in late spring 2018 following approval of the Harvard IRB. A proposal for the development of induced pluripotent stem cells in patients with FOH phenotype by Herb Lachman, MD the Albert Einstein College of Medicine Department of Psychiatry, Department of Neuroscience and Department of Genetics has been submitted for review. The study proposes to generate iPS cells to study the Fear of Harm (FOH) subgroup of bipolar disorder (BD) that is characterized by separation anxiety, circadian rhythm problems, parasomnias and thermoregulatory dysfunction. The iPS cells will be prepared from patients with FOH, BD without FOH, and matched controls. These will be induced to differentiate into hypothalamic neurons and cortical neurons that express the NMDA receptor, which is activated by the neurotransmitter glutamate. The focus on the hypothalamus and the NMDA receptor is duethe distinctive clinical and pharmacological characteristics of FOH. The hypothalamus is the brain structure that controls thermoregulation, sleep, and circadian rhythms, which are uniquely disrupted in FOH; the NMDA receptor is the primary target of ketamine, which dramatically reduces symptoms in most patients. The different types of neurons to be cultivated will be analyzed by a variety of means, including transcriptome analysis using RNA-seq a state of the art method for assessing the activity level of every gene in the genome, which is a powerful tool for understanding underlying disease mechanisms.This proposal has been preliminarily approved but awaits funding.The research paper, Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype, was accepted and has been published in Journal of Affective Disorders. See https://www.jbrf.org/wp-content/uploads/KetamineFOHLongitudinalStudyPub.pdfAn abstract of the paper follows:AbstractObjectives: Fear of Harm (FOH) is a pediatric onset phenotype of bipolar disorder (BD) characterized by BD plus treatment resistance, separation anxiety, aggressive obsessions, parasomnias, and thermal dysregulation. Intranasal ketamine (IK) in 12 youths with BD-FOH produced marked improvement during a two-week trial. Here we report on the open effectiveness and safety of IK in maintenance treatment of BD-FOH from the private practice of one author.Methods: As part of a chart review, patients 18 years or older and parents of younger children responded to a clinical effectiveness and safety survey. Effectiveness was assessed from analysis of responses to 49 questions on symptomatology plus qualitative content analyses of written reports and chart review. Adverse events (AEs) were analyzed by frequency, duration and severity. Results: Surveys were completed on 45 patients treated with IK for 3 months to 6.5 years. Almost all patients were much to very much improved clinically and in ratings of social function and academic performance. Significant reductions were reported in all symptom categories. There were 13 reports of persistent AEs, none of which resulted in discontinuation. Acute emergence reactions were sporadically observed in= up to 75%, but were mild and of brief duration. Limitations: Retrospective review from a single practice without placebo control with potential for response and recall bias. Conclusions: IK every 3-4 days at sub-anaesthetic doses appeared to be a beneficial and well-tolerated treatment. Use of IK may be considered as a tertiary alternative in treatment refractory cases. Randomized control trials are warranted.
Interesting data from their 2019 990 filing
According to the filing, the non-profit's mission is “To raise and distribute funds for the most promising research into the causes, treatment and prevention of early-onset bipolar disorder. in particular, we aim to further investigate and promote awareness of the fear of harm phenotype which our research has identified as being simultaneously associated with a distinct biomaker as well as the symptoms of childhood-onset bipolar disorder.”.
When referring to its actions, they were described as: “To raise and distribute funds for the most promising research into the causes, treatment and prevention of early-onset bipolar disorder. in particular, we aim to further investigate and promote awareness of the fear of harm phenotype which our research has identified as being simultaneously associated with a distinct biomaker as well as the symptoms of childhood-onset bipolar disorder.”.
- According to the law, the state of operation reported by the non-profit is NY.
- As per the filing, the address of the non-profit for 2019 is 277 MARTINE AVENUE 226, WHITE PLAINS, NY, 10601.
- According to their form, the non-profit as of 2019 has a total of 1 employees.
- Does not operate a hospital.
- Does not operate a school.
- Does not collect art.
- Does not provide credit counseling.
- Does not have foreign activities.
- Is not a donor-advised fund.
- Is not a private foundation.
- Expenses are between $100,000 and $250,000.
- Revenue is less than $100,000.
- Revenue less expenses is -$94,283.
- The CEO's salary plan within the organization is not subject to review and endorsement by a neutral party.
- The organization has 6 independent voting members.
- The organization has a written policy that addresses conflicts of interest.
- The organization is required to file Schedule B.
- The organization is required to file Schedule O.
- The organization pays $49,976 in salary, compensation, and benefits to its employees.
- The organization pays $28,449 in fundraising expenses.
- The organization provides Form 990 to its governing body.
- The organization has minutes of its meetings.
- The organization's financial statements were reviewed by an accountant.